AAN: Race May Affect Response to Anti-CD20 Therapy for MS, NMOSD
B-cell repopulation occurs more often in African American vs White patients between 6 and 12 months after anti-CD20 infusion
Multiple Sclerosis
Ponvory Now Available for Relapsing Forms of Multiple Sclerosis
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 modulator.
Tongue-Delivered Neuromodulation Therapy Gets FDA Clearance for MS-Related Gait Deficit
PoNS is a portable, noninvasive, prescription-only device intended to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older.
Ponvory Approved for Relapsing Forms of Multiple Sclerosis
Ponesimod is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator.
MS Therapy Plegridy Approved for Intramuscular Administration
The approval for IM use was based on data from an open-label, crossover study that assessed the bioequivalence of single doses of 125mcg of Plegridy administered as an SC and IM injection.
Stem Cell Transplant May Slow Disability in Multiple Sclerosis
Long-term outcomes assessed in 210 patients with MS who underwent autologous hematopoietic stem cell transplantation.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
FDA Approves Shorter Infusion Time for MS Drug Ocrevus
The approval was based on data from the phase 3b ENSEMBLE PLUS study that compared the frequency and severity of infusion-related reactions for a 2-hour Ocrevus infusion time to the previously approved 3.5-hour infusion time in patients with relapsing-remitting MS.
New Drug Product: Bafiertam
This slideshow shows drug information for Bafiertam. Click here for the complmultiete Bafiertam monograph.
New Drug Product: Kesimpta
This slideshow shows drug information for Kesimpta. Click here for the complete Kesimpta monograph.
